Rodin Therapeutics Inc. has landed a multi-year neuronal epigenetics R&D deal with Biogen Inc. that includes an undisclosed up-front payment for an option to buy the small cognitive disorders specialist as well as potential milestone payments of up to $485 million should the acquisition come to pass.